Pharmaceutical company Lannett Company Inc (NYSE:LCI) stated on Tuesday that it achieved net income of USD28.7m (USD0.75 per diluted share) for its fiscal year ended 30 June 2018.
This reflects an improvement when compared with net loss of USD0.6m (USD0.02 per share) for fiscal 2017.
GAAP net sales of USD684.6m were recorded for fiscal 2018, up from GAAP net sales of USD637.3m for fiscal 2017.
For fiscal 2017, R&D expenses were USD29.2m, a decline over R&D expenses of USD42.1m for fiscal 2017.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government